P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

• T. Facon,
• S. K. Kumar,
• T. Plesner,
• P. Moreau,
• N. Bahlis,
• H. Goldschmidt,
• M. O’Dwyer,
• A. Perrot,
• C. P. Venner,
• K. Weisel,
• J. R. Mace,
• N. Raje,
• M. Tiab,
• M. Macro,
• L. Frenzel,
• X. Leleu,
• H. Pei,
• F. Borgsten,
• S. Z. Usmani

Affiliations

T. Facon

1 University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

S. K. Kumar

2 Department of Hematology, Mayo Clinic Rochester, Rochester, MN, United States of America

T. Plesner

3 Vejle Hospital and University of Southern Denmark, Vejle, Denmark

P. Moreau

4 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

N. Bahlis

5 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

H. Goldschmidt

6 University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT), Heidelberg, Germany

M. O’Dwyer

7 Department of Medicine/Haematology, NUI, Galway, Ireland

A. Perrot

8 CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France

C. P. Venner

9 Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

K. Weisel

10 Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

J. R. Mace

11 Florida Cancer Specialists, St. Petersburg, FL

N. Raje

12 Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, United States of America

M. Tiab

13 CHD Vendée, La Roche sur Yon

M. Macro

14 Centre Hospitalier Universitaire (CHU) de Caen, Caen

L. Frenzel

15 Department of Clinical Haematology, Hopital Necker-Enfants Malades, Paris

X. Leleu

16 CHU Poitiers, Hôpital la Milétrie, Poitiers, France

H. Pei

17 Janssen Research & Development, LLC, Titusville, NJ, United States of America

F. Borgsten

18 Janssen-Cilag, Birkerød, Denmark

S. Z. Usmani

19 Memorial Sloan Kettering Cancer Center, New York, NY, United States of America